These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 8689811

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide].
    Bertschy G, Vandel S, Jounet JM, Allers G.
    Encephale; 1990; 16(1):43-5. PubMed ID: 2109680
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K, Tybring G, Härtter S, Andersson K, Svensson JO, Widén J, Bertilsson L.
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [Abstract] [Full Text] [Related]

  • 4. Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients.
    Vandel S, Bertschy G, Jounet JM, Allers G.
    Ther Drug Monit; 1988 Oct; 10(4):386-9. PubMed ID: 3144066
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Analysis of the Mechanism of Prolonged Persistence of Drug Interaction between Terbinafine and Amitriptyline or Nortriptyline.
    Mikami A, Hori S, Ohtani H, Sawada Y.
    Biol Pharm Bull; 2017 Oct; 40(7):1010-1020. PubMed ID: 28674244
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline.
    Grauer MT, Uhr M.
    J Psychopharmacol; 2004 Mar; 18(1):66-74. PubMed ID: 15107187
    [Abstract] [Full Text] [Related]

  • 11. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
    Reed RC, Dutta S, Cavanaugh JH, Locke C, Granneman GR.
    Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Toxic tricyclic drug plasma level caused by fluoxetine].
    Hambrecht M.
    Psychiatr Prax; 1995 Nov; 22(6):252-3. PubMed ID: 8570758
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
    Dutta S, Reed RC, O'Dea RF.
    Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.